Volixibat potassium is a Small Molecule owned by Mirum Pharmaceuticals, and is involved in 10 clinical trials, of which 7 were completed, and 3 are ongoing.

Volixibat potassium (SHP-626, LUM-002) is a selective inhibitor of apical sodium-dependent bile acid transporter (ASBT). Increased intestinal bile acid absorption and expansion of the bile acid pool is implicated in hypercholesterolemia. The ileal apical sodium-dependent bile acid transporter is primarily responsible for active reabsorption of the majority of bile acids.

The revenue for Volixibat potassium is expected to reach a total of $362m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Volixibat potassium NPV Report.

Volixibat potassium was originated by Sanofi and is currently owned by Mirum Pharmaceuticals.

Volixibat potassium Overview

Volixibat potassium (SHP-626, LUM-002) is under development for primary sclerosing cholangitis and its associated pruritus and primary biliary cholangitis. It is administered through the oral route as a capsule. The drug candidate selectively targets apical sodium-dependent bile acid transporter (ASBT). The human apical sodium-dependent bile acid transporter (SLC10A2) belongs to the solute carrier family (SLC) of transporters and is an important carrier protein expressed in the small intestine.

It was also under development for the treatment of nonalcoholic steatohepatitis (NASH) by Shire, adult cholestasis (intrahepatic cholestasis of pregnancy), and Type 2 diabetes.

Mirum Pharmaceuticals Overview

Mirum Pharmaceuticals is biopharmaceutical company that develops a pipeline of novel therapies for debilitating liver diseases. The company’s pipeline products include Maralixabat, minimally absorbed, orally administered investigational drug and Volixibat, a minimally absorbed agent designed to selectively inhibit ASBT. It develops products to treat rare cholestatic liver diseases that include progressive familial intrahepatic cholestasis (PFIC), alagille syndrome (ALGS), biliary atresia (BA), primary sclerosing cholangitis (PSC) and intrahepatic cholestasis of pregnancy (ICP). Mirum Pharmaceuticals is headquartered in Foster City, California, the US.

The company reported revenues of (US Dollars) US$19.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$65.4 million in FY2021, compared to an operating loss of US$104.3 million in FY2020. The net loss of the company was US$84 million in FY2021, compared to a net loss of US$103.3 million in FY2020. The company reported revenues of US$18.8 million for the third quarter ended September 2022, an increase of 7.4% over the previous quarter.

Quick View – Volixibat potassium

Report Segments
  • Innovator
Drug Name
  • Volixibat potassium
Administration Pathway
  • Oral
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.